Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK111 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Gumokimab (Primary)
- Indications Psoriasis; Psoriatic arthritis
- Focus Adverse reactions; First in man
- Sponsors Akesobio Australia
- 18 Sep 2020 Status changed from recruiting to completed.
- 26 Oct 2018 Status changed from not yet recruiting to recruiting.
- 20 Aug 2018 New trial record